＜＜Back

Next＞＞

Vol. 35　Suppl. 1　2007

Evaluation of Glucose Lowering Effects of Mitiglinide in Type 2 Diabetes Patients
―Placebo－controlled, Parallel Group Comparative Dose－response Study―

T. Tanaka, et al．

Jpn Pharmacol Ther 2007　35(s1) s5-21

---

Long-term Study of a Rapid and Short Acting Insulin Secretagogue Mitiglinide in Type 2 Diabetes Patients

T. Tanaka, et al．

Jpn Pharmacol Ther 2007　35(s1) s23-37

---

Clinical Pharmacological Study of Mitiglinide in Type 2 Diabetes Patients with Voglibose Monotherapy

Y. Tohi, et al.

Jpn Pharmacol Ther 2007　35(s1) s39-49

---

Concomitant Effects of a Rapid and Short Acting Insulin Secretagogue Mitiglinide in Type 2 Diabetes Patients with Inadequate Control of Blood Glucose with Voglibose Monotherapy
―Phase II / III Double Blind Comparative Study―

K. Kaku, et al.

Jpn Pharmacol Ther 2007　35(s1) s51-72

---

Long－term Concomitant Administration Study of a Rapid and Short Acting Insulin Secretagogue Mitiglinide in Combination with an α－Glucosidase Inhibitor Voglibose in Type 2 Diabetes Patients
―Extension Study of Phase II / III Double Blind Comparative Study―

K. Kaku, et al.

Jpn Pharmacol Ther 2007　35(s1) s73-91

---

Concomitant Effects of a Rapid and Short Acting Insulin Secretagogue Mitiglinide in Type 2 Diabetes Patients with Inadequate Control with α－Glucosidase Inhibitor Monotherapy
―Phase III Open Label Study―

T. Osonoii, et al.

Jpn Pharmacol Ther 2007　35(s1) s93-104